AWM
IRWD icon

Abound Wealth Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Abound Wealth Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-34
Closed -$151 – 1300
2024
Q4 		$151 Hold
34
– – ﹤0.01% 1168
2024
Q3 		$141 Hold
34
– – ﹤0.01% 1266
2024
Q2 		$222 Hold
34
– – ﹤0.01% 1079
2024
Q1 		$297 Hold
34
– – ﹤0.01% 1139
2023
Q4 		$389 Buy
+34
New +$336 ﹤0.01% 1036

Other funds holding IRWD

SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Abound Wealth Management's IRWD Position: Q1 2025 in Review

Abound Wealth Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2025, closing a stake of 34 shares — an estimated $151 sold.

Abound Wealth Management first reported a position in IRWD in Q4 2023 and held it in 5 quarters. The position peaked at $389 in Q4 2023. 200 funds tracked by Wall St. Rank hold IRWD as of Q1 2025.

  • Abound Wealth Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Abound Wealth Management sold 34 Ironwood Pharmaceuticals shares in Q1 2025, an estimated $151.
  • Abound Wealth Management first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Abound Wealth Management's Ironwood Pharmaceuticals position peaked at $389 in Q4 2023.
  • 200 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2025.

Based on Abound Wealth Management's 13F filing for Q1 2025, filed 17 Apr 2025.